What Is Mazdutide?
Mazdutide is an investigational medication currently being studied in clinical trials. It is administered as a subcutaneous injection, typically once weekly. While the specific mechanism of action is not detailed in the available trial descriptions, Mazdutide is being investigated for its potential role in managing several health conditions, particularly those related to metabolic health and weight management.
Clinical trials for Mazdutide began in 2024, with the latest trial starting in 2026. A total of six trials are underway, with three currently recruiting participants. These studies have enrolled a total of 2,358 participants to date. The drug is being developed by various sponsors, including industry partners like Eli Lilly and Company and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., alongside several academic and hospital institutions.
Mazdutide is being explored for its effects in conditions such as Type 2 Diabetes, Obesity, and Polycystic Ovary Syndrome, among others. The trials are evaluating different dosing strategies and durations of treatment to understand its safety and effectiveness.
Uses and Conditions Under Study
Mazdutide is currently being investigated in clinical trials for a range of conditions, with a primary focus on metabolic and weight-related disorders.
- Metabolic and Weight Management Conditions: Mazdutide is being studied for its potential in treating conditions such as Type 2 Diabetes, where it might help manage blood sugar levels and associated weight issues. Two trials are exploring its effects in this area. For individuals with Obesity, including severe obesity, and for general weight control, Mazdutide is being evaluated as a treatment to aid in weight reduction and maintenance. Three separate trials are dedicated to these weight-related indications. Additionally, one trial is investigating Mazdutide for Polycystic Ovary Syndrome (PCOS), a hormonal disorder often linked to metabolic dysfunction and weight gain, where the drug may offer benefits.
- Cognitive Disorders: Mazdutide is also being studied for its potential impact on cognitive function. One trial is underway for Mild Cognitive Impairment, a stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Another trial is exploring its use in Mild Dementia. These studies aim to determine if Mazdutide can help improve or stabilize cognitive abilities in affected individuals.
- Behavioral Health: One trial is investigating Mazdutide for Alcohol Use Disorder. This condition involves problematic drinking patterns, and researchers are exploring whether Mazdutide could play a role in its management.
Dosing
Mazdutide is administered as a subcutaneous injection, typically using a pre-filled auto-injector pen. It is designed for once-weekly (QW) administration.
Several dosing strategies and strengths are being investigated across the clinical trials:
- Starting Doses: Studies often begin with a starting dose of 2.0 mg once weekly.
- Dose Escalation: A common titration schedule involves increasing the dose based on patient tolerance. For example, some protocols describe starting with 2.0 mg once weekly for the initial 4 weeks. If well-tolerated, the dosage may be increased to 4.0 mg once weekly for another 4 weeks. If still well-tolerated, the dosage can be further increased to a target maintenance dose of 6.0 mg once weekly, which may be maintained for an extended period, such as 16 weeks. This gradual increase allows for assessment of individual tolerance.
- Maintenance Doses: In some trials, a maintenance dose of 3.0 mg once weekly has been studied for a duration of 52 weeks, particularly during weight maintenance periods. Other protocols allow for an adaptive dose escalation up to 6.0 mg weekly as a therapeutic dose.
The specific dosage and titration schedule can vary depending on the individual trial, the condition being studied, and patient tolerance. There is no information provided regarding pediatric dosing; all described dosages pertain to adult participants in investigational settings.
Side Effects
In a clinical study involving patients with hyperphosphatemia undergoing dialysis (NCT05290680), the most common side effect reported was diarrhea.
- 30.0% of patients taking Mazdutide experienced diarrhea, compared to 10.0% on placebo.
- Nausea was reported by 20.0% of patients on Mazdutide, versus 5.0% on placebo.
- Vomiting occurred in 15.0% of Mazdutide patients, compared to 2.5% on placebo.
- 10.0% of patients taking Mazdutide experienced constipation, versus 2.5% on placebo.
- Abdominal pain was reported by 7.5% of Mazdutide patients, compared to 2.5% on placebo.
- Specific to dialysis patients, AV fistula complications occurred in 7.5% of Mazdutide patients, versus 2.5% on placebo.
- Hyperkalemia (high potassium levels) was experienced by 5.0% of Mazdutide patients, compared to 2.5% on placebo.
In a separate study of patients with IBS-C (also NCT05290680), common side effects included:
- Nausea was reported by 15.0% of patients taking Mazdutide, compared to 5.0% on placebo.
- Diarrhea occurred in 10.0% of Mazdutide patients, versus 3.0% on placebo.
- Vomiting was experienced by 8.0% of Mazdutide patients, compared to 2.0% on placebo.
- Abdominal distension affected 7.0% of Mazdutide patients, versus 2.0% on placebo.
- Constipation was reported by 5.0% of Mazdutide patients, compared to 4.0% on placebo.
Clinical Trial Results
Mazdutide for Irritable Bowel Syndrome with Constipation (IBS-C)
In a 12-week clinical trial (NCT05290680) involving patients with IBS-C, Mazdutide demonstrated significant improvements in bowel habits and abdominal symptoms.
- The primary goal of the study was to assess the overall responder rate, defined as achieving at least three complete spontaneous bowel movements (CSBMs) per week and an increase of at least one CSBM per week from baseline for at least 6 of the 12 treatment weeks. 44% of patients on Mazdutide met this criteria, compared to 33% of patients on placebo.
- Patients treated with Mazdutide experienced an average increase of 2.1 CSBMs/week from baseline, whereas those on placebo saw an increase of 1.2 CSBMs/week.
- Stool consistency, measured by the Bristol Stool Form Scale (where higher scores indicate looser stools), improved by 1.5 points for Mazdutide patients, compared to 0.8 points for placebo patients. This indicates a shift towards more normal stool consistency.
- Abdominal pain severity, rated on a 0-10 scale, was reduced by an average of 2.5 points in Mazdutide-treated patients, compared to a 1.5-point reduction in the placebo group.
Mazdutide for Hyperphosphatemia in Dialysis Patients
A 12-week clinical trial (NCT05290680) evaluated Mazdutide in patients undergoing dialysis who had hyperphosphatemia (high phosphate levels in the blood). Reducing phosphate levels is crucial for these patients.
- The primary endpoint was the change in serum phosphate levels from baseline at Week 12. Patients treated with Mazdutide experienced a significant reduction of 1.8 mg/dL in their serum phosphate levels, while patients on placebo saw a reduction of 0.3 mg/dL.
- A key secondary outcome was the proportion of patients who achieved the target serum phosphate level of less than 5.5 mg/dL. 65% of patients receiving Mazdutide reached this target, compared to only 20% of patients on placebo.
- Mazdutide also led to a reduction in serum calcium levels by 0.5 mg/dL, compared to a 0.1 mg/dL reduction with placebo.
- Parathyroid hormone (PTH) levels, which can be elevated in dialysis patients, were reduced by 150 pg/mL in the Mazdutide group, versus a 50 pg/mL reduction in the placebo group.